Literature DB >> 24682286

Concise review: optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications.

Allison I Hoch1, J Kent Leach.   

Abstract

Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques.

Entities:  

Keywords:  Bioreactor; Expansion; Growth factor; Hypoxia; Mesenchymal stromal/stem cell; Progenitor

Mesh:

Year:  2014        PMID: 24682286      PMCID: PMC4006491          DOI: 10.5966/sctm.2013-0196

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  106 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use.

Authors:  Richard Cuthbert; Sally A Boxall; Hiang Boon Tan; Peter V Giannoudis; Dennis McGonagle; Elena Jones
Journal:  Cytotherapy       Date:  2012-01-24       Impact factor: 5.414

3.  Engineering of osteoinductive grafts by isolation and expansion of ovine bone marrow stromal cells directly on 3D ceramic scaffolds.

Authors:  S Scaglione; A Braccini; D Wendt; C Jaquiery; F Beltrame; R Quarto; Ivan Martin
Journal:  Biotechnol Bioeng       Date:  2006-01-05       Impact factor: 4.530

Review 4.  Bioreactor systems for bone tissue engineering.

Authors:  Juliane Rauh; Falk Milan; Klaus-Peter Günther; Maik Stiehler
Journal:  Tissue Eng Part B Rev       Date:  2011-06-10       Impact factor: 6.389

5.  Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation.

Authors:  S P Bruder; N Jaiswal; S E Haynesworth
Journal:  J Cell Biochem       Date:  1997-02       Impact factor: 4.429

Review 6.  Oxygen toxicity.

Authors:  L Frank; D Massaro
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965

7.  Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST.

Authors:  Chih-Chien Tsai; Yann-Jang Chen; Tu-Lai Yew; Ling-Lan Chen; Jir-You Wang; Chao-Hua Chiu; Shih-Chieh Hung
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

8.  Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells.

Authors:  Warren L Grayson; Feng Zhao; Bruce Bunnell; Teng Ma
Journal:  Biochem Biophys Res Commun       Date:  2007-05-22       Impact factor: 3.575

9.  Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells.

Authors:  Adetola B Adesida; Aillette Mulet-Sierra; Nadr M Jomha
Journal:  Stem Cell Res Ther       Date:  2012-03-02       Impact factor: 6.832

10.  Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation.

Authors:  Birgit Kulterer; Gerald Friedl; Anita Jandrositz; Fatima Sanchez-Cabo; Andreas Prokesch; Christine Paar; Marcel Scheideler; Reinhard Windhager; Karl-Heinz Preisegger; Zlatko Trajanoski
Journal:  BMC Genomics       Date:  2007-03-12       Impact factor: 3.969

View more
  41 in total

1.  Bone Morphogenetic Protein-2 Promotes Human Mesenchymal Stem Cell Survival and Resultant Bone Formation When Entrapped in Photocrosslinked Alginate Hydrogels.

Authors:  Steve S Ho; Nina L Vollmer; Motasem I Refaat; Oju Jeon; Eben Alsberg; Mark A Lee; J Kent Leach
Journal:  Adv Healthc Mater       Date:  2016-09-01       Impact factor: 9.933

2.  Comparison of percentage of CD90-positive cells and osteogenic differentiation potential between mesenchymal stem cells grown on dish and nonwoven fabric.

Authors:  Bo Fu; Masashi Fujiwara; Mutsumi Takagi
Journal:  Cytotechnology       Date:  2020-03-13       Impact factor: 2.058

3.  Adipose-derived stromal cells promote allograft tolerance induction.

Authors:  Thomas A Davis; Khairul Anam; Yelena Lazdun; Jeffrey M Gimble; Eric A Elster
Journal:  Stem Cells Transl Med       Date:  2014-11-19       Impact factor: 6.940

Review 4.  Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis.

Authors:  Mitsuru Mizuno; Nobutake Ozeki; Ichiro Sekiya
Journal:  Regen Ther       Date:  2022-06-17       Impact factor: 3.651

Review 5.  Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?

Authors:  Damla Alkaya; Cansu Gurcan; Pelin Kilic; Acelya Yilmazer; Gunhan Gurman
Journal:  3 Biotech       Date:  2020-03-06       Impact factor: 2.406

6.  Cell-secreted matrices perpetuate the bone-forming phenotype of differentiated mesenchymal stem cells.

Authors:  Allison I Hoch; Vaishali Mittal; Debika Mitra; Nina Vollmer; Christopher A Zikry; J Kent Leach
Journal:  Biomaterials       Date:  2015-10-09       Impact factor: 12.479

7.  Hydrogel biophysical properties instruct coculture-mediated osteogenic potential.

Authors:  Kaitlin C Murphy; Roberta S Stilhano; Debika Mitra; Dejie Zhou; Samir Batarni; Eduardo A Silva; J Kent Leach
Journal:  FASEB J       Date:  2015-10-06       Impact factor: 5.191

8.  Immunogenic potential of human bone marrow mesenchymal stromal cells is enhanced by hyperthermia.

Authors:  Ian McClain-Caldwell; Lynn Vitale-Cross; Balazs Mayer; Miklos Krepuska; Michael Boyajian; Vamsee Myneni; Daniel Martin; Karoly Marko; Krisztian Nemeth; Eva Mezey
Journal:  Cytotherapy       Date:  2018-10-31       Impact factor: 5.414

9.  Modulating Mesenchymal Stem Cell Behavior Using Human Hair Keratin-Coated Surfaces.

Authors:  Pietradewi Hartrianti; Ling Ling; Lyn Mei Ming Goh; Kok Seng Amos Ow; Rebekah Margaret Samsonraj; Wan Ting Sow; Shuai Wang; Victor Nurcombe; Simon M Cool; Kee Woei Ng
Journal:  Stem Cells Int       Date:  2015-06-01       Impact factor: 5.443

10.  Effect of expansion media and fibronectin coating on growth and chondrogenic differentiation of human bone marrow-derived mesenchymal stromal cells.

Authors:  Valentina Basoli; Elena Della Bella; Eva Johanna Kubosch; Mauro Alini; Martin J Stoddart
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.